Representing Biond at ASCO 2026 will be:
• Dr. Tehila Ben Moshe, Co-Founder and Chief Executive Officer
• Dr. Natalia Ashtamker, Vice President of Clinical Development
• Sharon Hashmueli, Vice President of Regulatory Affairs
ASCO is the world’s leading clinical oncology conference, bringing together oncology researchers, clinicians, pharmaceutical companies, and industry leaders to discuss the latest advances in cancer treatment and drug development.
Biond’s team will be available to discuss the Company’s growing portfolio of first-in-class immunotherapies, including BND-22, an anti-ILT2 antibody currently being evaluated in Phase 2 clinical studies, and BND-67, a first-in-class anti-CD28 shedding antibody currently being evaluated in a first-in-human clinical trial.
To schedule a meeting with the Biond team during ASCO 2026, please contact us at partnering@biondbio.com.
